No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Aptamer Group, the developer of 'Optimer' binders for the life sciences industry, flagged solid operational progress in an update on Friday, reporting that since its 2.6m fundraising in July, it had achieved cost-reduction targets, streamlined scientific production, and executed a new commercial growth strategy.
The AIM-traded firm, which was holding its annual general meeting, said the efforts had enhanced its ability to deliver high-quality, optimised products to an expanding customer base.
It reported success in attracting major global pharmaceutical clients and building relationships with diagnostic, healthcare, and niche biotech partners.
Key milestones included developing a vertical market platform for fibrosis in collaboration with AstraZeneca, advancing a deodorant Optimer product toward human trials with Unilever, and producing an Optimer delivery conjugate for an undisclosed genetic medicines partner, now preparing for preclinical trials.
"Our increased commercial traction has secured newly signed contracts, currently up to the value of 0.47m, which will ensure that the group's cash runway remains generous, allowing any licensing opportunities to evolve and potentially crystalise over this extended period," said non-executive chairman Dr Adam Hargreaves.
"The board looks forward to updating shareholders on further progress in due course."
At 1154 GMT, shares in Aptamer Group were down 3.1% at 0.3p.
Reporting by Josh White for Sharecast.com.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.